Singapore has attracted eight of the top ten global drug makers, aiming to be Southeast Asia's leading biomedicine hub. Despite significant investment and initiatives, the city-state faces challenges in translating scientific strengths into commercially successful medicines. Experts suggest Singapore must leverage its capabilities to overcome the limitations of its small domestic market and capitalize on growing competition for sector investment. AI
RANK_REASON The cluster discusses a significant industry trend regarding Singapore's role as a biomedicine hub and the challenges faced by major drug makers. [lever_c_demoted from significant: ic=1 ai=0.1]
- Bayer
- Drug makers and drug regulators: too close for comfort. A study of the Canadian situation
- Singapore
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →